Paysign, Inc. (PAYS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Paysign, Inc. is a vertically integrated provider of prepaid card products, pharma patient affordability offerings, and digital banking services. The company operates as a single reporting segment. As of November 6, 2025, there were 55,042,888 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $21.60 million | $15.26 million | $59.27 million | $42.78 million |
| Gross Profit | $12.15 million | $8.47 million | $35.60 million | $23.00 million |
| Gross Margin | 56.3% | 55.5% | 60.1% | 53.8% |
| Net Income | $2.22 million | $1.44 million | $6.19 million | $2.44 million |
| Diluted EPS | $0.04 | $0.03 | $0.10 | $0.04 |
| Operating Cash Flow (YTD) | $4.36 million (2025) vs $8.63 million (2024) | |||
| Cash & Restricted Cash | $118.55 million (as of Sept 30, 2025) | |||
| Unrestricted Cash | $7.53 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 41.6% in Q3 2025 compared to Q3 2024. This was driven by a 141.9% surge in Pharma industry revenue ($7.92M vs $3.27M) and a 12.4% increase in Plasma industry revenue ($12.86M vs $11.44M).
- Profitability: Net income rose 54.2% in Q3 2025. Operating income improved significantly by 129.3% to $1.58 million.
- Acquisition Impact: The company acquired Gamma Innovation LLC on March 19, 2025, for a total preliminary consideration of $15.56 million. This added $4.49 million in goodwill and $11.07 million in identifiable intangible assets to the balance sheet.
- Expense Increases: Operating expenses rose 35.8% in Q3, primarily due to increased compensation, stock-based compensation ($1.27M vs $0.57M), and depreciation/amortization related to the acquisition and software capitalization.
- Cash Flow: Operating cash flow decreased YTD by $4.27 million to $4.36 million, largely due to timing differences in pass-through claim reimbursements and a $17.0 million increase in accounts receivable.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes available unrestricted cash ($7.53M) combined with forecasted revenues will sustain operations for the next 24 months. No immediate capital raise is planned, though the company evaluates opportunities to diversify.
- Strategic Focus: Continued investment in technology, cybersecurity, and sales/marketing. The company is leveraging the Gamma acquisition to expand donor engagement and resource management solutions in the plasma market.
- Legal Proceedings:
- Securities Class Action: A settlement of $3.75 million (fully covered by D&O insurance) was approved by the court in April 2024.
- Derivative Actions: Four stockholder derivative actions are pending. A proposed settlement was preliminarily approved by the court in August 2025, with a final approval hearing scheduled for November 14, 2025.
- Risk Factors: Concentration of credit risk with one financial institution; concentration of accounts receivable (one pharma customer represented 14% of AR); and reliance on pass-through payment timing for cash flow.
Investor Verification Checklist
- Verify the final valuation and measurement period adjustments for the Gamma Innovation LLC acquisition.
- Monitor the timing of collections on the $49.6 million accounts receivable balance, particularly the 14% concentration with a single pharma customer.
- Review the final court approval of the stockholder derivative settlement scheduled for November 14, 2025.
- Assess the sustainability of the 141.9% year-over-year growth in Pharma revenue and the associated customer care cost increases.
- Confirm the status of the $3.0 million remaining under the stock repurchase program (authorized March 2023).